CAZ Investments raises $29M fund | Wall Street Beat Wall Street Beat

CAZ Investments raised a nearly $29 million funding round it plans to use to back medical companies that already have products on the market.

The Houston-based asset management firm reeled in $28.7 million from 61 unnamed investors, according to a regulatory filing.

CAZ Investments chairman Christopher Zook said the firm plans to use the cash to invest in commercialized companies.

Sign up to get our free newsletters delivered straight to your inbox

"For this fund, we don’t have as long a lag time. Typically, when you make a venture capital investment it’s a concept and you have to wait for it to go through the entire process. We’re investing only in products in the marketplace already generating revenue," Zook told the International Venture Capital Post.

 Will new SEC rules kill angel investing?
New rules adopted by the SEC could threaten angel investing in startups, according to the Angel Capital Assn., including a ban on self-accreditation by potential investors.
Read more

 VC-backed IPOs up during Q2
Venture capital-backed initial public offerings were up during the 2nd quarter, with 22 firms with VC backers went public for a total valuation of roughly $9.6 billion.
Read more

 Nikon eyes the medical device market
Nikon could look to bolster flagging compact camera sales by following rivals Canon and Sony into the medical device business.
Read more

 Mindray closes $105M Zonare buy
Mindray (NYSE:MR) said it closed a $105 million buyout of Zonare Medical Systems and its ultrasound technology.
Read more

 Analysts’ ups and downs

  • Allscripts (NSDQ:MDRX): ISI Group downgrades from “buy” to “neutral” rating, raises price target to $16.50 from $15.50.
  • C.R. Bard (NYSE:BCR): Atlantic Securities initiates coverage with “neutral” rating, $115 price target; Morgan Stanley reiterates "underweight" rating.
  • Cerner (NSDQ:CERN): First Analysis downgrades from “overweight” to “equal weight” rating.
  • Danaher (NYSE:DHR): Morgan Stanley reiterates "overweight" rating, raises price target from $68 to $72.
  • Fresenius (NYSE:FMS): Jefferies Group upgrades from “hold” to “buy” rating.
  • Hologic (NSDQ:HOLX): Piper Jaffray downgrades to "neutral" from "overweight" rating, $21 price target.
  • Intuitive Surgical (NSDQ:ISRG): Leerink Swann maintains “market perform” rating.
  • Johnson & Johnson (NYSE:JNJ): Deutsche Bank downgrades to "neutral" from "buy" rating, $93 price target; Jefferies raises price target to $95, ups estimates, sets "hold" rating; Leerink Swann reiterates “outperform” rating, raises price target to $98 from $94.
  • Mallinckrodt plc (NYSE: MNK): UBS AG initiates coverage with “neutral” rating, $43.00 price target.
  • NuVasive Inc. (NSDQ:NUVA): BMO Capital Markets downgrades from “market perform” to “underperform” rating, raises price target from $18 to $22
  • Optos plc (LON:OPTS): Canaccord Genuity reaffirms "buy" rating, £2.48 ($3.75) price target
  • ResMed (NYSE:RMD): Needham & Co. initiates coverage with “hold” rating.
  • Stryker (NYSE:SYK): TheStreet reaffirms "buy" rating.
  • Sunshine Heart (ASX:SHC): Oppenheimer initiates coverage with "outperform" rating, $11 price target.
  • Volcano (NSDQ:VOLC): Oppenheimer initiates coverage with "outperform" rating, $24 price target.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply